Skip to content

Blood Loss Reduction via Local Application of Diluted Adrenaline Solution Compared to Placebo in Elderly with Intertrochanteric Fracture Underwent PFNA Fixation: A Randomized Controlled Trial

Blood Loss Reduction via Local Application of Diluted Adrenaline Solution Compared to Placebo in Elderly with Intertrochanteric Fracture Underwent PFNA Fixation: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260104003
Enrollment
108
Registered
2026-01-04
Start date
2023-05-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly femoral fracture Hip Fractures Elderly patient Intertrochanteric fracture PFNA Intraoperative blood loss Blood loss prevention Adrenaline Local injection RCT

Interventions

Group 1 will receive 1% xylocaine with diluted adrenaline (1:200,000) infiltrated at the planned surgical incision sites to reduce intraoperative bleeding. The volume of injected solution for each p
1% Xylocaine with adrenaline,NSS injection

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
60 Years to 110 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 60 years or older. 2. Patients presenting with a closed intertrochanteric fracture of the femur resulting from low energy trauma. 3. Patients undergoing operative treatment with a proximal femoral nail antirotation PFNA device. 4. All surgeries performed by the highly experienced orthopedic surgeon. 5. Patients must receive either diluted adrenaline containing local anesthetic or nSS placebo for intraoperative blood-loss reduction.

Exclusion criteria

Exclusion criteria: 1. Patients with additional injuries to other body regions besides the intertrochanteric femoral fracture (multiple trauma). 2. Patients with significant preoperative medical complications. 3. Patients who cannot receive diluted adrenaline containing local anesthetic, such as those with a known drug allergy. 4. Patients with conditions affecting coagulation, including those with cancer, hemophilia, or a history of venous thromboembolism (VTE).

Design outcomes

Primary

MeasureTime frame
Intraoperative blood loss Intraoperatively Direct suction of blood from the surgical field Measurement of blood collected on a plastic surgical drape Gauze swabs blood volume absorbed will be interpreted using a visual estimation

Secondary

MeasureTime frame
Adverse event of the injection Post operative, during admission Clinical signs and symptoms,Wound complication Follow up at out patient department Surgical wound evaluation,Other medical condition Post operative, during admission UTI, Sepsis, Pneumonia, VTE,Blood product usage During admission Pack red cell unit given

Countries

Thailand

Contacts

Public ContactPatcharapol Arunwatthanangkul

Royal Thai Army Pramongkutklao hospital

jade77638@gmail.com027639300

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026